Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences

Macarena I. de la Fuente, Aya Haggiagi, Adrienne Moul, Robert J. Young, Charif Sidani, Arnold Markoe, Francisco Vega, Lisa M. DeAngelis, Izidore S. Lossos

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Dural lymphoma (DL) is a rare type of primary CNS lymphoma arising from the dura mater. The optimal treatment is uncertain. A retrospective review was performed on 26 DL patients. Seventeen patients underwent resection and nine had a biopsy. Twenty three patients could be assessed for a response to treatment after surgery. Thirteen received focal radiotherapy (RT), six whole brain RT (WBRT), three chemotherapy alone and one chemotherapy followed by WBRT. Twenty two achieved complete response (CR) and one a partial response (PR). Four patients relapsed (two local and two systemic). Median follow up was 64 months, with median progression free survival (PFS) and OS not reached. Three year PFS was 89% (95% CI 0.64–0.97). All patients are alive at last follow-up, demonstrating that DL is an indolent tumor with long survival. CR is achievable with focal therapy in the majority of cases, but there is a risk for relapses and long-term follow-up is recommended.

Original languageEnglish (US)
Pages (from-to)882-888
Number of pages7
JournalLeukemia and Lymphoma
Issue number4
StatePublished - Apr 3 2017


  • Dural lymphoma
  • focal radiotherapy
  • marginal zone lymphoma
  • primary central nervous system lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences'. Together they form a unique fingerprint.

Cite this